Successful TRPV1 antagonist treatment for cardiac hypertrophy and heart failure in mice

Heart failure is becoming a global epidemic. It exerts a staggering toll on quality of life, and substantial medical and economic impact. In a pre-clinical model of cardiac hypertrophy and heart failure, we were able to overcome loss of heart function by administering the TRPV1 antagonist BCTC (4-(3...

Full description

Saved in:
Bibliographic Details
Published inChannels Vol. 7; no. 1; pp. 17 - 22
Main Authors Horton, Jaime S., Buckley, Cadie L., Stokes, Alexander J.
Format Report
LanguageEnglish
Published Taylor & Francis 01.01.2013
Subjects
apoptosis
cardiac hypertrophy
fibrosis
heart failure
pressure overload
TRPV1
Online AccessGet full text

Cover

More Information
Summary:Heart failure is becoming a global epidemic. It exerts a staggering toll on quality of life, and substantial medical and economic impact. In a pre-clinical model of cardiac hypertrophy and heart failure, we were able to overcome loss of heart function by administering the TRPV1 antagonist BCTC (4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide). The results presented here identify TRPV1 antagonists as new treatment options for cardiac hypertrophy and heart failure.
ISSN:1933-6950
1933-6969
DOI:10.4161/chan.23006